The relationship between ERCC1 and RRM1 genes and the clinical features of bladder cancer and the effect of gemcitabine intra-bladderperfusion in non-muscle invasive bladder cancer

doi:10.3877/cma.j.issn.1674-3253.2020.03.004

Abstract

Abstract:

Objective

To explore the expression of excision repair cross complementing one (ERCC1) and ribonucleotide reductase M1(RRM1) genes in bladder cancer and the relationship with the chemotherapy efficacy of gemcitabine intravesical infusion in non-muscle invasive bladder cancer.

Methods

A total of 86 patients diagnosed as bladder cancer from July 2014 to July 2018 were enrolled in the retrospective study, including 50 patients with nonmuscle-invasive type and 36 patients with invasive bladder cancer, at the same time 30 cases of benign bladder tumor were enrolled. For patients with non-invasive cancer, transurethral resection of bladder tumor and bladder perfusion of gemcitabine chemotherapy were used. The quantitative expressions of ERCC1 and RRM1 mRNAs were detected by real-time fluorescence quantitative PCR. The follow-up time was 15-63 months, median time was 41.5 months. Progression free survival time(PFS), median survival time, total recurrence rate and survival rate were recorded. The correlation between ERCC1 and RRM1 gene expressions and perfusion effect were analyzed.

Results

Compared with patients with benign bladder tumor, RRM1 was higher expressed and ERCC1 was lower in patients with bladder cancer, and RRM1 was significantly higher in invasive patients than non-invasive patients (P<0.05), ERCC1 was lower than non-invasive patients (P<0.05). Moreover,expression levels of ERCC1 and RRM1 were closely related to tumor stage and grade, but not related to patient's gender, age and tumor diameter (P<0.05). 7 cases (7/50) after perfusion recurred. The expression level of RRM1 was significantly higher in recurrence group than non-recurrence group, while ERCC1 was lower than non-recurrence group (P<0.05).

Conclusion

The low expression of ERCC1 and high expression of RRM1 in bladder cancer are not only closely related to tumor stage and pathological grade, but also to perfusion effect of gemcitabine. The detection of ERCC1 and RRM1 expressions has important reference value for early prediction of chemotherapy effect, and prolonging survival time of patients.

Key words: Bladder cancer, Gemcitabine, ERCC1, RRM1, Intra-bladder perfusion

Shichang Zhang, Jiang Zheng. The relationship between ERCC1 and RRM1 genes and the clinical features of bladder cancer and the effect of gemcitabine intra-bladderperfusion in non-muscle invasive bladder cancer[J]. Chinese Journal of Endourology(Electronic Edition), 2020, 14(03): 176-180.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2020.03.004

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2020/V14/I03/176

Figures/Tables 3

References 20

[1]	Lewis GD, Haque W, Verma V, et al. The role of adjuvant radiation therapy in locally advanced bladder cancer[J].Bladder Cancer, 2018, 4(2): 205-213.
[2]	陈晓芳, 陈万青, 周薇薇, 等. 2013年中国膀胱癌发病和死亡流行状况分析[J]. 中国肿瘤, 2018, 27(2): 81-85.
[3]	刘佳生. 膀胱癌患者术后应用吡柔比星和吉西他滨膀胱灌注化疗对患者的影响[J].海峡药学, 2018, 30(11): 144-145.
[4]	魏蕾, 李自雄, 秦叔逵, 等. 吉西他滨单药或联合白蛋白结合型紫杉醇治疗东亚人群晚期胰腺癌临床疗效的荟萃分析[J].临床肿瘤学杂志, 2019, 24(2): 137-144.
[5]	元芬, 周咏梅. 紫杉醇与吉西他滨联合抗肿瘤作用机制及共载给药系统的研究进展[J]. 中国新药杂志, 2019, 28(9): 1081-1086.
[6]	刘勇, 王斌, 陈思思, 等. TOP2a、Nek2及RRM1在胃癌癌组织中表达及临床意义[J]. 临床和实验医学杂志, 2019, 18(2): 146-149.
[7]	韩靖, 江俊伟, 李文辉. 非小细胞肺癌RRM1、ERCC1的表达及对含铂化疗方案预后的影响[J]. 现代诊断与治疗, 2019, 30(8): 1305-1307.
[8]	孙琳, 魏琪, 刘利敏, 等. 神经胶质瘤组织及外周血中ERCC1的表达水平与替莫唑胺化疗效果的相关性研究[J]. 卒中与神经疾病, 2019, 26(4): 449-453.
[9]	刘志飞, 张志宏, 邢力永, 等. RRM1 mRNA与吉西他滨药物膀胱灌注治疗膀胱癌疗效的关系[J]. 天津医科大学学报, 2019, 25(1): 51-53.
[10]	王安鸽,武喆,王莉,等.核糖核苷酸还原酶抑制剂治疗肿瘤的研究进展[J].肿瘤防治研究,2019,46(8):741-745.
[11]	关云哲, 杨东彪, 王振中. 表浅性膀胱癌细胞中DNA核酸内切酶ERCC1及膜连蛋白-1的表达及与顺铂耐药的关系[J]. 中国老年学杂志, 2013, 33(10): 2315-2317.
[12]	刘晓岗, 王彧, 刘春桂, 等. ERCC1和TUBB3基因联合检测在中晚期食管癌同步放化疗中的应用[J]. 实用癌症杂志, 2019, 34(9): 1428-1431.
[13]	孔蕾, 王俊杰, 王济东, 等. miR-503靶向ERCC1抑制食管鳞状细胞癌放疗抵抗作用的机制[J]. 中国肿瘤生物治疗杂志, 2019, 26(09): 969-975.
[14]	秦菁. ERCC1、RRM1与BRCA1蛋白联合检测在非小细胞肺癌治疗中的价值分析[J]. 泰山医学院学报, 2019, 40(10): 762-763.
[15]	Matsumura N, Nakamura Y, Kohjimoto Y, et al. Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic-bladder cancer patients treated with gemcitabine-containing combination chemotherapy[J]. Int J Urol, 2017, 24(3): 230-235.
[16]	Urun Y, Leow JJ, Fay AP, et al. ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2017, 120(12): 120-126.
[17]	Yang Z, Fu B, Zhou L, et al. RRM1 predicts clinical outcome of high and intermediate-risk non-muscle-invasive bladder cancerpatients treated with intravesical gemcitabine monotherapy[J]. BMC Urol,2019, 19(1): 69.
[18]	Minami K, Shinsato Y,Yamamoto M, et al. Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors[J]. J Pharmacol Sci, 2015, 127(3): 319-325.
[19]	朱研峰, 刘志飞, 邢力永, 等. 膀胱癌组织中TopoⅡα和RRM1蛋白表达水平及其临床意义[J].东南大学学报(医学版), 2019, 38(2): 296-302.
[20]	田楠楠, 周磊, 杨丹妮, 等. 沉默RRM1可逆转乳腺癌细胞MCF-7/R对紫杉醇的耐药性[J]. 南方医科大学学报, 2019, 39(3): 304-312.

组别		例数	RRM1（×10^-3）	F值	P值	ERCC1（×10^-3）	F值	P值
肿瘤分期		?	?	35.236	<0.001<	?	6.539	0.002
?	Tis	14	13.21±3.14	?	?	3.01±0.84	?	?
?	Ta	17	17.69±3.83	?	?	2.55±0.76	?	?
?	T1	19	19.53±4.42	?	?	1.98±0.45	?	?
浸润性		36	21.23±5.69	?	?	1.55±0.34	?	?
病理分级		?	?	23.236	<0.001<	?	5.869	0.005
?	G1	20	12.63±3.28	?	?	3.06±0.92	?	?
?	G2	18	15.21±3.69	?	?	2.83±0.76	?	?
?	G3	12	17.79±4.15	?	?	2.59±0.64	?	?
性别		?	?	0.569	0.521	?	0.469	0.598
?	男	28	15.31±4.78	?	?	2.81±0.62	?	?
?	女	22	15.23±4.16	?	?	2.75±0.59	?	?
年龄（岁）		?	?	0.725	0.229	?	0.623	0.342
?	< 61	20	15.21±4.22	?	?	2.74±0.58	?	?
?	≥61	30	15.34±4.92	?	?	2.82±0.64	?	?
肿瘤最大直径(cm)		?	?	0.925	0.123	?	0.825	0.213
?	< 2.8	21	15.18±4.65	?	?	2.72±0.55	?	?
?	≥2.8	29	15.36±5.02	?	?	2.83±0.67	?	?

组别		例数	RRM1（×10^-3）	F值	P值	ERCC1（×10^-3）	F值	P值
肿瘤分期		?	?	35.236	<0.001<	?	6.539	0.002
?	Tis	14	13.21±3.14	?	?	3.01±0.84	?	?
?	Ta	17	17.69±3.83	?	?	2.55±0.76	?	?
?	T1	19	19.53±4.42	?	?	1.98±0.45	?	?
浸润性		36	21.23±5.69	?	?	1.55±0.34	?	?
病理分级		?	?	23.236	<0.001<	?	5.869	0.005
?	G1	20	12.63±3.28	?	?	3.06±0.92	?	?
?	G2	18	15.21±3.69	?	?	2.83±0.76	?	?
?	G3	12	17.79±4.15	?	?	2.59±0.64	?	?
性别		?	?	0.569	0.521	?	0.469	0.598
?	男	28	15.31±4.78	?	?	2.81±0.62	?	?
?	女	22	15.23±4.16	?	?	2.75±0.59	?	?
年龄（岁）		?	?	0.725	0.229	?	0.623	0.342
?	< 61	20	15.21±4.22	?	?	2.74±0.58	?	?
?	≥61	30	15.34±4.92	?	?	2.82±0.64	?	?
肿瘤最大直径(cm)		?	?	0.925	0.123	?	0.825	0.213
?	< 2.8	21	15.18±4.65	?	?	2.72±0.55	?	?
?	≥2.8	29	15.36±5.02	?	?	2.83±0.67	?	?

Please choose a citation manager

Content to export